Search Web Site
Personal tools
Sections
map
front page map

Click on the map for a list of participating countries.

 
What is the ISCHEMIA Study?
  • An international comparative effectiveness study

  • The purpose of ISCHEMIA is to determine the best way to manage stable ischemic heart disease

  • Patients with moderate or severe ischemia on stress test imaging may be eligible for participation

 If you are a physician and would like more information, please visit the For Physicians section. If you are a patient and would like to learn more about the ISCHEMIA study, please e-mail ischemia@nyumc.org

Drs. George Dangas, Judith Hochman, and Gregg Stone discuss the ISCHEMIA Trial and why every interventionalist should actively participate.

Why is the ISCHEMIA Study Important?

Ischemic heart disease (IHD) is the leading cause of death and disability worldwide and affects 17,600,000 Americans, resulting in about 450,000 deaths in the United States annually. Globally, 7.2 million deaths are caused by IHD each year.

Medical therapy (medication and lifestyle changes) should always be used to treat IHD. Many doctors routinely use an invasive approach in addition to medical therapy to treat IHD; however, it is not known if this approach is better than medical therapy alone as the initial treatment of patients with stable ischemic heart disease (SIHD). ISCHEMIA is designed to find the answer. Click here to learn more about the ISCHEMIA study.

Study Coordinator Webinar

Join us for our monthly study coordinator webinar the last Thursday of each month! Contact the ISCHEMIA CCC for details.

ISCHEMIA Enrollment Update

Congratulations to our top randomizing sites!

  • Northwick Park Hospital (Middlesex, United Kingdom): Dr. Roxy Senior, Dr. Elghamaz & SCs Grace Young, Raisa Kavalakkat, Christopher Kinsey and Sothinathan Gurunathan (41)
  • Coronary and Structural Heart Diseases Department, Institute of Cardiology (Warsaw, Poland): Dr. Marcin Demkow & Dr. Radek Pracon (24)
  • Montreal Heart Institute (Montreal, Canada): Dr. Gilbert Gosselin, Dr. Patrick Garceau  & SCs Rima Amche, Magalie Corfias & Nathalie St. Jean (24)
  • Centre Hospitalier Regional de Trois-Rivieres (Trois-Rivieres, Canada): Dr. Ariel Diaz, Dr. Gilbert Gosselin & SC Isabelle Roy (22)
  • University Hospital (London, Canana): Dr. Dennis Humen, William Kostuk & SC Sandy Carr (18)
  • CSSS du Sud de Lanaudiere (Terrebonne, Canada): Dr. Denis Phaneuf, Dr. Gilbert Gosselin & SCs Margaux David & Mijanou Delorme (15)
  •  Ospedali Riuniti of Ancona (Ancona, Italy): Dr. Gian Perna, Dr. Alberta Pangrazi & SCs Marco Mazzanti & Francesa Pietrucci (15)
  • Atlanta V.A. Medical Center (Decatur, USA): Dr. Kreton Mavromatis & SC Charlene Brown (13)
  • Hospital Universitario La Paz (Madrid, Spain): Dr. Jose Luis Lopez Sendon & SCs Almudena Castro & Silvia Valbuena (12)
  • Medical University of Lodz (Lodz, Poland): Dr. Jarozlaw Drozdz, Dr. Ryszard Jaszewski & SC Aleksandra Filipiak (11) 

As of April 14, there are 647 participants randomized across Argentina, Australia, Austria, Belgium, Canada, China, France, Germany, Hungary, India, Israel, Italy, Japan, Lithuania, Macedonia, Mexico, New Zealand, Poland, Russia, Saudia Arabia, Serbia, Singapore, Spain, Sweden, Switzerland, the United Kingdom and the United States.